Mid-Cap Bio-Techne Corp Faces Market Challenges Amidst Promising Growth

With a market capitalization of $9.3 billion, Bio-Techne Corporation (TECH) stands as a significant player in the life sciences sector. Headquartered in Minneapolis, Minnesota, the company offers tools and bioactive reagents to support both research and clinical diagnostics. It operates through two main segments: Protein Sciences and Diagnostics & Genomics.

As a mid-cap stock, Bio-Techne falls within the range of $2 billion to $10 billion, which is typical for companies of its size. This classification underlines its role in aiding drug discovery and facilitating accurate clinical tests, supported by a diverse range of products in its portfolio.

Active Investor: FREE newsletter going behind the headlines on the hottest stocks to uncover new trade ideas

Recently, Bio-Techne’s stock prices declined by 31.5% from their peak of $85.57 reached on May 15, 2024. Over the last three months, shares have slipped 19.7%, contrasting sharply with the S&P 500 Index’s ($SPX) 6% decline.

Year-to-date, shares of TECH have seen an 18.6% drop, while the S&P 500 posted a modest 4.6% decrease during the same timeframe. Additionally, over the last 52 weeks, TECH’s stock has fallen 16.7%, significantly trailing the S&P 500’s 6.8% return.

The stock’s recent struggles are further evidenced by its performance below the 50-day and 200-day moving averages since early February.

On a more positive note, TECH shares surged over 3.7% following Q2 2025 earnings announced on February 5, showing revenues of $297 million and an adjusted EPS of $0.42, surpassing Wall Street forecasts. The Protein Sciences Segment achieved a year-over-year growth of 7%, totaling $211.6 million, driven by favorable conditions in the biopharma market and strong demand for cell and gene therapy workflow solutions. Additionally, the Diagnostics & Spatial Biology segment reported impressive commercial performance, achieving 12% organic and reported growth.

In comparison with industry peers, Adaptive Biotechnologies Corporation (ADPT) has outperformed Bio-Techne. Year-to-date, ADPT stock has gained 23.9%, and over the past year, shares have climbed 131.5%.

Despite Bio-Techne’s underperformance relative to the broader market in the last year, analysts are optimistic about its future. The stock carries a consensus rating of “Strong Buy” from 14 analysts, with a mean price target of $83.61, indicating an exciting 42.6% upside potential from current price levels.

On the date of publication,

Aditya Sarawgi

did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy

here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.